TRILLIUM THERAPEUTICS
Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted proteins, and peptides. It involves in therapeutic areas, including autoimmune disease, cancer, necrotizing enterocolitis, and transplantation. Trillium Therapeutics Inc. was formerly known as Transplantation Technologies Inc. and changed its name in May 2003. The company was founded in 1996 and is based in Toronto, Canada.
TRILLIUM THERAPEUTICS
Industry:
Biopharma Biotechnology Clinical Trials Health Care Therapeutics
Founded:
2004-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.trilliumtherapeutics.com
Total Employee:
51+
Status:
Active
Contact:
416-595-0627
Email Addresses:
[email protected]
Total Funding:
281.98 M USD
Technology used in webpage:
Euro Google Maps Google Maps API Cloudflare Cloudflare Bot Manager Cloudflare SSL Oracle Cloud
Similar Organizations
Sagimet Biosciences
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Atacama Therapeutics
Atacama Therapeutics focuses on developing treatments for hyperhidrosis.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Epizyme
Epizyme is a biopharmaceutical company focusing on treatments for blood cancer and tumors.
GlycoMimetics
GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers.
Krystal Biotech
Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-01-28 | Fluorinov Pharma | Fluorinov Pharma acquired by Trillium Therapeutics | 32 M USD |
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Equity - Trillium Therapeutics
Pfizer Breakthrough Growth Initiative
Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - Trillium Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Trillium Therapeutics
BDC Venture Capital
BDC Venture Capital investment in Seed Round - Trillium Therapeutics
Official Site Inspections
http://www.trilliumtherapeutics.com
- Host name: 192.29.61.237
- IP address: 192.29.61.237
- Location: Zurich Switzerland
- Latitude: 47.4049
- Longitude: 8.4631
- Timezone: Europe/Zurich
- Postal: 8102
More informations about "Trillium Therapeutics"
Pfizer Completes Acquisition of Trillium Therapeutics
Nov 17, 2021 Acquisition enhances Pfizer’s Oncology portfolio with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Pfizer Inc. (NYSE: PFE) …See details»
Trillium Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 416-595-0627 Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company.See details»
Pfizer to Acquire Trillium Therapeutics Inc.
Aug 23, 2021 Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological …See details»
Pfizer to buy Canadian drug developer Trillium Therapeutics
Aug 23, 2021 Pfizer Inc. said on Monday it would buy Canadian drug developer Trillium Therapeutics Inc. in a $2.26 billion deal to strengthen its arsenal of blood cancer therapies.See details»
Trillium Therapeutics Inc. | LinkedIn
Trillium Therapeutics Inc. | 5,041 followers on LinkedIn. Clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. | Trillium Therapeutics Inc. …See details»
Trillium Securityholders Approve Acquisition by Pfizer - Yahoo …
CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company …See details»
Trillium Securityholders Approve Acquisition by Pfizer
Oct 26, 2021 For more information: www.trilliumtherapeutics.com. Caution Regarding Forward-Looking Information. To the extent any statements made in this report contain information that …See details»
Trillium Therapeutics - Craft
Trillium Therapeutics is a clinical-stage immuno-oncology company. It develops protein therapeutics, such as monoclonal antibodies, secreted proteins, peptides, and small molecules …See details»
Pfizer to buy cancer drug developer Trillium in $2.3 bln deal
Aug 23 (Reuters) - Pfizer Inc , opens new tab said on Monday it would buy Canadian drug developer Trillium Therapeutics Inc , opens new tab in a $2.26 billion deal to strengthen its …See details»
Trillium Therapeutics Appoints Dr. Ingmar Bruns as Chief Medical …
Nov 2, 2020 All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Trillium disclaims any obligation to revise or update any such forward-looking …See details»
Pfizer to Acquire Trillium Therapeutics Inc. | Business Wire
Aug 23, 2021 Rosemary Harrison +1 (857) 412-7029 x225 [email protected]. Site Navigation. Home. Home; Submit a Press Release; Services; News. All News; News with …See details»
Pfizer Acquires Trillium, Gains Anti-CD47 Assets - PubMed
Pfizer is paying $2.26 billion to acquire Trillium Therapeutics, maker of two clinical-stage fusion proteins directed against CD47, the "do not eat me" signal that cancer cells co-opt to shield …See details»
Pfizer Completes Acquisition of Trillium Therapeutics
Nov 17, 2021 Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology companSee details»
Pfizer Acquires Trillium, Gains Anti-CD47 Assets
Nov 1, 2021 Abstract. Pfizer is paying $2.26 billion to acquire Trillium Therapeutics, maker of two clinical-stage fusion proteins directed against CD47, the “do not eat me” signal that cancer …See details»
Trillium Therapeutics Announces Formation of Scientific
Nov 2, 2020 Tom Reynolds, MD, PhD – Dr. Reynolds served as Chief Medical Officer of Seattle Genetics, where he was responsible for building and leading an integrated clinical …See details»
Pfizer to Acquire Trillium Therapeutics Inc. - Yahoo Finance
Aug 23, 2021 Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological …See details»
What is Trillium Therapeutics? Company Culture, Mission, Values
Glassdoor gives you an inside look at what it's like to work at Trillium Therapeutics, including salaries, reviews, office photos, and more. This is the Trillium Therapeutics company profile.See details»
Trillium Therapeutics Announces Formation of Scientific Advisory …
Nov 2, 2020 All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Trillium disclaims any obligation to revise or update any such forward-looking …See details»
Trillium Therapeutics Provides Data Update, Announces Phase
Apr 28, 2021 TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1...See details»
Trillium Therapeutics Announces Dosing of First Patient in Phase …
Apr 28, 2021 Company Contact:Rosemary HarrisonSVP, Corporate Development and StrategyTrillium Therapeutics Inc. 857-412-7029 [email protected] …See details»